|
Synonyms: AD-65585 | ALN-65585 | ALN-G01 | Oxlumo®
lumasiran is an approved drug (EMA, FDA & UK MHRA (2020))
Compound class:
Nucleic acid
Comment: Lumasiran is a double-stranded small interfering ribonucleic acid (siRNA) drug. It targets HAO1 mRNA as a mechanism to reduce the hepatic oxalate overproduction that is responsible for disease pathology in patients with primary hyperoxaluria type 1 (PH1) [1]. We have been unable to locate a full chemical SMILES for the drug, or its HELM notation.
|
| References |
|
1. D'Ambrosio V, Ferraro PM. (2022)
Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside. Int J Nephrol Renovasc Dis, 15: 197-206. [PMID:35747094] |
